latest news releases from the newsroom
MetaPower International, Inc.
MetaPower International, Inc. Signs Contract to Begin $30,000 Feasibility Study At North America's Largest Nuclear Facility
LAS VEGAS, Sept. 9, 2008 (GLOBE NEWSWIRE) -- MetaPower International, Inc. (Pink Sheets:MTPR) is pleased to announce that the Company has signed a contract with Bruce Power to begin a new feasibility study in its nuclear power facilities in Ontario, Canada. The study will begin in September of this year and will be conducted by the Company's subsidiary, MetaPower Canada. Bruce Power currently leases "The Bruce" nuclear facilities from Ontario Power Generation and is listed as the largest nuclear facility in North America and second largest in the world.
Kratos Defense & Security Solutions, Inc.
Kratos' Public Safety Business Awarded Physical Security and Surveillance Contracts Valued At Approximately $4.4 Million
SAN DIEGO, Sept. 9, 2008 (GLOBE NEWSWIRE) -- Kratos Defense and Security Solutions, Inc. (Nasdaq:KTOS), a leading national defense, information technology and homeland security solutions provider, today announced that its Public Safety & Security business has been awarded contracts from four leading national digital infrastructure companies and one major medical facility to provide a range of physical security and surveillance services. The combined value of the contracts is approximately $4.4 million. The contracts were received by Kratos' Mid-Atlantic office.
Nabi Biopharmaceuticals and NIAID to Advance PentaStaph Vaccine Research
ROCKVILLE, Md., Sept. 9, 2008 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced today that the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health, has entered into a collaboration with Nabi to advance the Company's promising PentaStaph(tm) vaccine candidate for the prevention and treatment of S. aureus infections in the community and hospital settings. The focus of the collaboration is to conduct pre-clinical toxicology evaluations of two new S. aureus antigens as components of the first-in-class, multivalent vaccine, targeting S. aureus infections. NIAID will fund the pre-clinical toxicology evaluations of the vaccine components manufactured and provided by Nabi. The two novel antigens are designed to protect against two of the most virulent and debilitating toxins produced by the bacteria: Panton-Valentine Leukocidin, found predominantly in community-acquired methicillin-resistant S. aureus (MRSA), and alpha toxin, produced by almost all S. aureus isolates. Pre-clinical toxicology testing of these components will help enable the initiation of Phase 1 clinical trials for these new antigens in early 2009 which is one of the Company's three development milestones for 2008.